Drugs / MSI-1256F
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01678963 | Nov 2012 → Mar 2015 | wet macular degeneration | Ohr Pharmaceutical Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00333476 | May 2006 → ? | macular degeneration | Genaera Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00094120 | Oct 2004 → Feb 2007 | age-related macular degeneration | Genaera Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT00089830 | Aug 2004 → May 2007 | age-related macular degeneration | Genaera Corporation | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSI-1256F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00089830 ↗ |
| Known as | Squalamine Lactate | “MSI-1256F (Squalamine Lactate)” NCT00089830 ↗ |
| Action | Inhibit | “an inhibitor of new blood vessel formation” NCT01678963 ↗ |
| Route | Other | “topical ophthalmic squalamine lactate eye drops” NCT01678963 ↗ |